ClinicalTrials.gg
CompletedNCT03928743BE MOBILE 2Updated Sep 25, 2026Results posted

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Subjects With Active Ankylosing Spondylitis

A Phase 3 interventional study of Bimekizumab and Placebo in Ankylosing Spondylitis, sponsored by UCB Biopharma SRL. Completed at 83 sites in 14 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-25.

Sponsored by UCB Biopharma SRL (part of UCB S.A.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
332
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies in Spondylitis, Ankylosing by UCB S.A. — none open to participants now, none under way, none of them phase 3. Spondylitis, Ankylosing · UCB S.A..

Started
2019
the only one that year
Phase 3
4 of 11
none open now
Registered
10th of 11
by date

Among the 11 studies in Spondylitis, Ankylosing by UCB S.A., this one is the only one that started in 2019, is one of 4 in phase 3, and was the 10th registered.

Spondylitis, Ankylosing

533 studies on the registry are indexed under Spondylitis, Ankylosing; 99 are open to participants now.

Browse Spondylitis, Ankylosing studies →

Open to participants now

None of the 11 studies in Spondylitis, Ankylosing by UCB S.A. is open now. The open studies under Spondylitis, Ankylosing, anywhere →

Who these studies take

Of the 63 Spondylitis, Ankylosing studies recruiting now, 25 (40%) set no upper age limit and 32 (51%) stop at 75 or younger; 10 take children under 18; 15 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies in Spondylitis, Ankylosing by UCB S.A. as a file.
02

Study summary

The purpose of the study is to demonstrate the efficacy, safety and tolerability of bimekizumab administered subcutaneously (sc) compared to placebo in the treatment of subjects with active ankylosing spondylitis (AS).

03

Conditions studied

  • Ankylosing Spondylitis

Keywords

  • Ankylosing spondylitis
  • AS
  • Bimekizumab
  • Axial spondyloarthritis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female patients at least 18 years of age
  • Subject has ankylosing spondylitis (AS) as per the Modified New York (mNY) criteria with documented radiologic evidence, and at least 3 months of symptoms with age at symptom onset less than 45 years
  • Subjects has moderate-to-severe active disease defined by Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) >=4 AND spinal pain >=4 on a 0 to 10 Numeric Rating Scale
  • Subjects had to have either failed to respond to 2 different nonsteroidal anti-inflammatory drugs (NSAIDs) given at the maximum tolerated dose for a total of 4 weeks or have a history of intolerance to or a to NSAID therapy
  • Patients who have taken a tumor necrosis factor alpha (TNFα) inhibitor must have experienced an inadequate response or intolerance to treatment given at an approved dose for at least 12 weeks
  • Patients currently taking NSAIDs, cyclooxygenase 2 (COX-2) inhibitors, analgesics, , methotrexate (MTX), leflunomide (LEF), sulfasalazine (SSZ), hydroxychloroquine (HCQ) AND/OR apremilast can be allowed if they fulfill specific requirements prior to study entry

Exclusion criteria

Exclusion Criteria:

  • Total ankylosis of the spine
  • Treatment with more than 1 TNFα inhibitor and/or more than 2 additional non-TNFα biological response modifiers, or any interleukin (IL)-17 biological response modifier at any time are excluded
  • Active infection or history of recent serious infections
  • Viral or C or (HIV) infection
  • Any live (includes attenuated) vaccination within the 8 weeks prior to entering the study or TB (Bacillus Calmette-Guerin) vaccination within 1 year prior entering the study
  • Known tuberculosis (TB) infection, at high risk of acquiring TB infection, or current or history of nontuberculous mycobacterium (NTMB) infection
  • Subject has any active or history of malignancy within 5 years prior to the Screening Visit EXCEPT treated and considered cured cutaneous squamous or basal cell carcinoma or in situ cervical cancer
  • Diagnosis of inflammatory conditions other than AxSpA, eg, rheumatoid arthritis. Patients with a diagnosis of Crohn's disease, ulcerative colitis, or other inflammatory bowel disease (IBD) are allowed as long as they have no active symptomatic disease when entering the study.
  • Presence of active suicidal ideation, or moderately severe major depression or severe major depression
  • Female patients who are breastfeeding, pregnant, or planning to become pregnant during the study
  • Subject has a history of chronic alcohol or drug abuse within 6 months prior to Screening
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
332 participants (actual)

Study arms

  • Experimental
    Bimekizumab

    Subjects randomized to this arm will receive bimekizumab during the Double-Blind Treatment Period and the Maintenance Period.

    Drug: Bimekizumab

  • Placebo comparator
    Placebo

    Subjects randomized to this arm will receive placebo during the Double-Blind Treatment Period and receive bimekizumab during the Maintenance Period.

    Drug: Bimekizumab · Other: Placebo

Interventions

  • Subjects will receive bimekizumab at pre-specified time-points.

    Also known as: BKZ, UCB4940

  • OtherPlacebo

    Subjects will receive placebo at pre-specified time-points during the Double-Blind Treatment Period.

    Also known as: PBO

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Assessment of SpondyloArthritis International Society 40% Response Criteria (ASAS40) Response at Week 16

    ASAS40 response was defined as relative improvements of at least 40% and absolute improvement of at least 2 units on a 0 to 10 Numeric Rating Scale (NRS), where 0 is "not active" and 10 is "very active" in at least 3 of the 4 domains: Patient's Global Assessment of Disease Activity (PGADA) assessed disease activity on a scale of 0 \[not active\] to 10 \[very active\], higher score=more disease activity, Pain assessment on a scale of 0 \[no pain\] to 10 \[most severe pain\], higher score=more severity, Function (Bath Ankylosing Spondylitis Functional Index (BASFI)) assessed participant's level of ability on a scale of 0 \[easy\] to 10 \[impossible\], Inflammation (morning stiffness intensity and duration, mean of Q5 and Q6 of Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) defined as 6 item questionnaire: measured disease activity on a scale of 0 \[none\] to 10 \[severe\], higher score=more disease activity) and no worsening at all in the remaining domain.

    Time frame: Week 16

Secondary outcomes

  1. Percentage of Participants With Assessment of SpondyloArthritis International Society 40% Response Criteria (ASAS40) Response in TNFα Inhibitor-naïve Participants at Week 16

    ASAS40 response was defined as relative improvements of at least 40% and absolute improvement of at least 2 units on a 0 to 10 NRS, where 0 is "not active" and 10 is "very active" in at least 3 of the 4 domains: PGADA assessed disease activity on a scale of 0 \[not active\] to 10 \[very active\], higher score=more disease activity, Pain assessment on a scale of 0 \[no pain\] to 10 \[most severe pain\], higher score=more severity, Function (BASFI) assessed participant's level of ability on a scale of 0 \[easy\] to 10 \[impossible\], Inflammation (morning stiffness intensity and duration, mean of Q5 and Q6 of BASDAI defined as 6 item questionnaire: measured disease activity on a scale of 0 \[none\] to 10 \[severe\], higher score=more disease activity) and no worsening at all in the remaining domain.

    Time frame: Week 16

  2. Percentage of Participants With Assessment of SpondyloArthritis International Society 20% Response Criteria (ASAS20) Response at Week 16

    ASAS20 response was defined as relative improvements of at least 20% and absolute improvement of at least 1 unit on a 0 to 10 NRS, where 0 is "not active" and 10 is "very active" in at least 3 of the 4 domains: PGADA assessed disease activity on a scale of 0 \[not active\] to 10 \[very active\], higher score=more disease activity, Pain assessment on a scale of 0 \[no pain\] to 10 \[most severe pain\], higher score=more severity, Function (BASFI) assessed participant's level of ability on a scale of 0 \[easy\] to 10 \[impossible\], Inflammation (morning stiffness intensity and duration, mean of Q5 and Q6 of BASDAI defined as 6 item questionnaire: measured disease activity on a scale of 0 \[none\] to 10 \[severe\], higher score=more disease activity) and no worsening at all in the remaining domain.

    Time frame: Week 16

  3. Change From Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Total Score at Week 16

    BASDAI is a validated self-reported instrument, which consisted of 6 questions to measure the disease activity of ankylosing spondylitis (AS) from the participant's perspective. It measured the severity of fatigue, spinal and peripheral joint pain and swelling, enthesitis, and morning stiffness (both severity and duration). Each question was rated using a numerical rating scale from 0 (none) to 10 (very severe), higher score=high disease activity. The BASDAI score was calculated by computing the mean of questions 5 and 6 and adding it to the sum of questions 1 to 4. This score was then divided by 5. The total BASDAI score was ranged from 0=none to 10= very severe, where higher score indicated high disease activity. A negative value indicated improvement and a positive value indicated worsening.

    Time frame: Baseline, Week 16

  4. Percentage of Participants With Assessment of SpondyloArthritis International Society (ASAS) Partial Remission (PR) at Week 16

    The Assessment of SpondyloArthritis International Society partial remission was defined as a score of less than or equal to (\<=) 2 units (on a scale of 0-10, where 0=no disease activity and 10=high disease activity) in each of the 4 domains. These 4 domains included: PGADA assessed disease activity on a scale of 0 \[not active\] to 10 \[very active\], higher score=more disease activity, Pain assessment on a scale of 0 \[no pain\] to 10 \[most severe pain\], higher score=more severity, Function (BASFI) assessed participant's level of ability on a scale of 0 \[easy\] to 10 \[impossible\], Inflammation (morning stiffness intensity and duration, mean of Q5 and Q6 of BASDAI defined as 6 item questionnaire: measured disease activity on a scale of 0 \[none\] to 10 \[severe\], higher score=more disease activity).

    Time frame: Week 16

  5. Percentage of Participants With Ankylosing Spondylitis Disease Activity Score Major Improvement (ASDAS-MI) at Week 16

    ASDAS-MI is achieved when there is a reduction (improvement) of greater than or equal to (\>=) 2.0 in the Ankylosing Spondylitis Disease Activity Score (ASDAS) relative to Baseline. ASDAS is calculated as the sum of the following components: 1) 0.121 × Total back pain (Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Q2 result), 2) 0.058 × Duration of morning stiffness (BASDAI Q6 result), 3) 0.110 × Patient's Global Assessment of Disease Activity (PGADA), 4) 0.073 × Peripheral pain/swelling (BASDAI Q3 result), 5) 0.579 × (natural logarithm of the C-reactive protein (CRP) \[mg/L\] + 1). Total back pain, PGADA, duration of morning stiffness, peripheral pain/swelling and fatigue are all assessed on a numerical scale (0 \[no disease activity\] to 10 \[high disease activity\] units). High ASDAS scores mean worse disease. If a participant achieves the ASDAS-MI it indicates a major improvement of their disease.

    Time frame: Week 16

  6. Percentage of Participants With Assessment of SpondyloArthritis International Society (ASAS) 5/6 Response at Week 16

    The Assessment of SpondyloArthritis International Society (ASAS) 5/6 response is defined as achieving at least 20% improvement in 5 of 6 domains: PGADA assessed disease activity on a scale of 0 \[not active\] to 10 \[very active\], higher score=more disease activity, Pain assessment on a scale of 0 \[no pain\] to 10 \[most severe pain\], higher score=more severity), Function (BASFI) assessed participant's level of ability on a scale of 0 \[easy\] to 10 \[impossible\], Inflammation (morning stiffness intensity and duration, mean of Q5 and Q6 of BASDAI defined as 6 item questionnaire: measured disease activity on a scale of 0 \[none\] to 10 \[severe\], higher score=more disease activity), spinal mobility (lateral spinal flexion) and high sensitivity C-reactive protein (hs-CRP)\].

    Time frame: Week 16

  7. Change From Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI) at Week 16

    The Bath Ankylosing Spondylitis Functional Index (BASFI) assesses physical function in comprising 10 items relating to activities during the past week. Each item ranged from 0 ('Easy') to 10 ('Impossible'). The BASFI is the mean of the 10 scores such that the total score ranges from 0 to 10, with lower scores indicating better physical function. A negative value in BASFI change from Baseline indicates an improvement from Baseline. The higher the negative value the better the improvement.

    Time frame: Baseline, Week 16

  8. Change From Baseline in Nocturnal Spinal Pain Score Numeric Rating Scale (NRS) at Week 16

    Nocturnal spinal pain experienced by ankylosing spondylitis (AS) participants is measured by one question: pain in the spine at night due to AS?. When responding, the participant is to consider the average amount of pain in the preceding week. It is assessed on a numerical scale of 0 (no pain) to 10 (most severe pain) units. A lower score indicates less pain and a negative change represents an improvement.

    Time frame: Baseline, Week 16

  9. Change From Baseline in Ankylosing Spondylitis Quality of Life (ASQoL) Total Score at Week 16

    The Ankylosing Spondylitis Quality of Life (ASQoL), a validated disease-specific 18-item questionnaire, has been developed specifically for measuring health-related quality of life (HRQoL) in participants with ankylosing spondylitis and has shown to be responsive in axial spondyloarthritis (axSpA). Each statement on the ASQoL is given a score of 1=Yes or 0=No. A score of "1" was given where the item was affirmed, indicating adverse quality of life. All item scores were summed to generate the total score ranging from 0 to 18 with a higher score indicating worse health-related quality of life. A negative change from baseline represents an improvement.

    Time frame: Baseline, Week 16

  10. Change From Baseline in the Short Form 36-Item Health Survey (SF-36) Physical Component Summary (PCS) Score at Week 16

    SF-36 is a 36-item HRQoL instrument with recall period of 4 weeks. Items are grouped into 8 domains: Physical Functioning (10 items), Role Physical (4 items), Bodily Pain (2 items), General Health (5 items), Vitality (4 items), Social Functioning (2 items), Role Emotional (3 items), Mental Health (5 items) and 1 item for Health Transition during last year. PCS and Mental Component Summary (MCS) scores are calculated from 8 domains (excluding Health Transition item). Each of SF-36 derived raw scores range from 0 to 100; higher score = better function. PCS score is calculated from 8 domain scores. It is standardized score ranging from 7.3 to 70.1, with a mean of 50 and SD of 10 in general US population, higher values = better function, and positive change reflects improvement. A PCS score mean below 47 indicates impaired physical functioning. Individual respondent's score that falls outside T-score range of 45 to 55 are outside average general US population range.

    Time frame: Baseline, Week 16

  11. Change From Baseline in Bath Ankylosing Spondylitis Disease Metrology Index (BASMI) at Week 16

    The Bath Ankylosing Spondylitis Disease Metrology Index characterizes the spinal mobility of participants with axial Spondyloarthritis (SpA) and Ankylosing Spondylitis. It is a disease-specific measure consisting of 5 clinical measures to reflect participant axial status: cervical rotation; tragus to wall distance; lateral lumbar flexion; lumbar flexion (modified Schober test); intermalleolar distance. According to the linear definition of the BASMI a score of 0 to 10 was calculated for each item based on the measurement. The mean of the 5 scores provides the total BASMI score (ranging from 0 to 10). The higher the BASMI score, the more severe the participant's limitation of movement due to their axial SpA. A negative value in BASMI change from Baseline indicates an improvement from Baseline. The higher the negative value, the better the improvement.

    Time frame: Baseline, Week 16

  12. Change From Baseline in the Maastricht Ankylosing Spondylitis Enthesitis (MASES) Index in the Subgroup of Participants With Enthesitis at Baseline at Week 16

    The Maastricht Ankylosing Spondylitis Enthesitis is an index that measures the severity (ie, intensity and extent) of enthesitis through the assessment of 13 entheses (bilateral costochondral 1, costochondral 7, anterior superior iliac spine, posterior iliac spine, iliac crest and proximal insertion of the Achilles tendon sites, and the fifth lumbar vertebral body spinous process), each scored as 0 or 1 and then summed for a possible score of 0 to 13. A higher score reflects higher severity and a negative change represents an improvement.

    Time frame: Baseline, Week 16

  13. Percentage of Participants With Enthesitis-free State at Week 16 Based on the Maastricht Ankylosing Spondylitis Enthesitis Index in the Subgroup of Participants With Enthesitis at Baseline

    The Maastricht Ankylosing Spondylitis Enthesitis is an index that measures the severity (ie, intensity and extent) of enthesitis through the assessment of 13 entheses (bilateral costochondral 1, costochondral 7, anterior superior iliac spine, posterior iliac spine, iliac crest and proximal insertion of the Achilles tendon sites, and the fifth lumbar vertebral body spinous process) each scored as 0 or 1 and then summed for a possible score of 0 to 13. Enthesitis free state is defined as having a MASES score of 0. A higher score reflects higher severity and a negative change represents an improvement.

    Time frame: Baseline, Week 16

  14. Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) During the Study

    TEAEs are defined as those AEs that have a start date on or following the first dose of study treatment through the final dose of study treatment + 140 days (covering the 20-week Safety follow up (SFU) period). TEAEs were analyzed and have been reported for Double Blind Treatment Period (Safety set),Maintenance Period (MP) (Maintenance Set) and Overall Period (Safety set) which includes all participants who received BKZ 60 mg Q4W during the study.

    Time frame: From Baseline (Day 1) until Safety-Follow-Up (up to Week 68)

  15. Percentage of Participants With Treatment-emergent Serious Adverse Events (SAEs) During the Study

    A serious adverse event (SAE) is any untoward medical occurrence that at any dose resulted in 1) Death, 2) Life-threatening (Life-threatening does not include a reaction that might have caused death had it occurred in a more severe form.), 3) Significant or persistent disability/incapacity, 4) Congenital anomaly/birth defect (including that occurring in a fetus), 5) Important medical event that, based upon appropriate medical judgment, may jeopardize the participant or participant may require medical or surgical intervention to prevent 1 of the other outcomes listed in the definition of serious (Important medical events may include, but are not limited to, potential Hy's Law \[see allergic bronchospasm requiring intensive treatment in an emergency room or at home, blood dyscrasias that do not result in inpatient hospitalization, or the development of drug dependency or drug abuse.)

    Time frame: From Baseline (Day 1) until Safety-Follow-Up (up to Week 68)

  16. Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) Leading to Withdrawal From Investigational Medicinal Product (IMP) During the Study

    TEAEs are defined as those AEs that have a start date on or following the first dose of study treatment through the final dose of study treatment + 140 days (covering the 20-week SFU period).

    Time frame: From Baseline (Day 1) until Safety-Follow-Up (up to Week 68)

07

Results

Posted Oct 10, 2024

Participant flow

The study started to enroll study participants in April 2019 and concluded in August 2022.

Double-Blind Treatment Period:Weeks 1-16
Participant flow — Double-Blind Treatment Period:Weeks 1-16
MilestonePlacebo (up to Week 16)Bimekizumab 160 mg Q4W (up to Week 16)Bimekizumab 160 mg Q4W (Week 16 up to Week 52)
Started1112210
Completed1092130
Not completed280
Withdrew: Due to covid-19 pandemic and site restrictions110
Withdrew: Withdrawal by subject130
Withdrew: Lack of efficacy010
Withdrew: Adverse event020
Withdrew: Adverse event, serious non-fatal010
Maintenance Period: Weeks 16-52
Participant flow — Maintenance Period: Weeks 16-52
MilestonePlacebo (up to Week 16)Bimekizumab 160 mg Q4W (up to Week 16)Bimekizumab 160 mg Q4W (Week 16 up to Week 52)
Started00319
Completed00298
Not completed0021
Withdrew: Pi decision due to non-compliance and covid 19001
Withdrew: Withdrawal by subject004
Withdrew: Lost to follow-up002
Withdrew: Lack of efficacy003
Withdrew: Adverse event009
Withdrew: Adverse event, serious non-fatal002

Outcome measures

PrimaryPercentage of Participants With Assessment of SpondyloArthritis International Society 40% Response Criteria (ASAS40) Response at Week 16

ASAS40 response was defined as relative improvements of at least 40% and absolute improvement of at least 2 units on a 0 to 10 Numeric Rating Scale (NRS), where 0 is "not active" and 10 is "very active" in at least 3 of the 4 domains: Patient's Global Assessment of Disease Activity (PGADA) assessed disease activity on a scale of 0 \[not active\] to 10 \[very active\], higher score=more disease activity, Pain assessment on a scale of 0 \[no pain\] to 10 \[most severe pain\], higher score=more severity, Function (Bath Ankylosing Spondylitis Functional Index (BASFI)) assessed participant's level of ability on a scale of 0 \[easy\] to 10 \[impossible\], Inflammation (morning stiffness intensity and duration, mean of Q5 and Q6 of Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) defined as 6 item questionnaire: measured disease activity on a scale of 0 \[none\] to 10 \[severe\], higher score=more disease activity) and no worsening at all in the remaining domain.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants With Assessment of SpondyloArthritis International Society 40% Response Criteria (ASAS40) Response at Week 16
percentage of participantsPlacebo (up to Week 16)Bimekizumab 160 mg Q4W (up to Week 16)
Percentage of Participants With Assessment of SpondyloArthritis International Society 40% Response Criteria (ASAS40) Response at Week 1622.544.8
Statistical analysis
  • Placebo (up to Week 16) vs Bimekizumab 160 mg Q4W (up to Week 16) · Regression, Logistic · p = <0.001 · Odds ratio (or): 2.88 · 95% CI 1.71 to 4.87
SecondaryPercentage of Participants With Assessment of SpondyloArthritis International Society 40% Response Criteria (ASAS40) Response in TNFα Inhibitor-naïve Participants at Week 16

ASAS40 response was defined as relative improvements of at least 40% and absolute improvement of at least 2 units on a 0 to 10 NRS, where 0 is "not active" and 10 is "very active" in at least 3 of the 4 domains: PGADA assessed disease activity on a scale of 0 \[not active\] to 10 \[very active\], higher score=more disease activity, Pain assessment on a scale of 0 \[no pain\] to 10 \[most severe pain\], higher score=more severity, Function (BASFI) assessed participant's level of ability on a scale of 0 \[easy\] to 10 \[impossible\], Inflammation (morning stiffness intensity and duration, mean of Q5 and Q6 of BASDAI defined as 6 item questionnaire: measured disease activity on a scale of 0 \[none\] to 10 \[severe\], higher score=more disease activity) and no worsening at all in the remaining domain.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants With Assessment of SpondyloArthritis International Society 40% Response Criteria (ASAS40) Response in TNFα Inhibitor-naïve Participants at Week 16
percentage of participantsPlacebo (up to Week 16)Bimekizumab 160 mg Q4W (up to Week 16)
Percentage of Participants With Assessment of SpondyloArthritis International Society 40% Response Criteria (ASAS40) Response in TNFα Inhibitor-naïve Participants at Week 1623.445.7
Statistical analysis
  • Placebo (up to Week 16) vs Bimekizumab 160 mg Q4W (up to Week 16) · Regression, Logistic · p = <0.001 · Odds ratio (or): 2.80 · 95% CI 1.59 to 4.93
SecondaryPercentage of Participants With Assessment of SpondyloArthritis International Society 20% Response Criteria (ASAS20) Response at Week 16

ASAS20 response was defined as relative improvements of at least 20% and absolute improvement of at least 1 unit on a 0 to 10 NRS, where 0 is "not active" and 10 is "very active" in at least 3 of the 4 domains: PGADA assessed disease activity on a scale of 0 \[not active\] to 10 \[very active\], higher score=more disease activity, Pain assessment on a scale of 0 \[no pain\] to 10 \[most severe pain\], higher score=more severity, Function (BASFI) assessed participant's level of ability on a scale of 0 \[easy\] to 10 \[impossible\], Inflammation (morning stiffness intensity and duration, mean of Q5 and Q6 of BASDAI defined as 6 item questionnaire: measured disease activity on a scale of 0 \[none\] to 10 \[severe\], higher score=more disease activity) and no worsening at all in the remaining domain.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants With Assessment of SpondyloArthritis International Society 20% Response Criteria (ASAS20) Response at Week 16
percentage of participantsPlacebo (up to Week 16)Bimekizumab 160 mg Q4W (up to Week 16)
Percentage of Participants With Assessment of SpondyloArthritis International Society 20% Response Criteria (ASAS20) Response at Week 1643.266.1
Statistical analysis
  • Placebo (up to Week 16) vs Bimekizumab 160 mg Q4W (up to Week 16) · Regression, Logistic · p = <0.001 · Odds ratio (or): 2.66 · 95% CI 1.65 to 4.28
SecondaryChange From Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Total Score at Week 16

BASDAI is a validated self-reported instrument, which consisted of 6 questions to measure the disease activity of ankylosing spondylitis (AS) from the participant's perspective. It measured the severity of fatigue, spinal and peripheral joint pain and swelling, enthesitis, and morning stiffness (both severity and duration). Each question was rated using a numerical rating scale from 0 (none) to 10 (very severe), higher score=high disease activity. The BASDAI score was calculated by computing the mean of questions 5 and 6 and adding it to the sum of questions 1 to 4. This score was then divided by 5. The total BASDAI score was ranged from 0=none to 10= very severe, where higher score indicated high disease activity. A negative value indicated improvement and a positive value indicated worsening.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · scores on a scale
Change From Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Total Score at Week 16
scores on a scalePlacebo (up to Week 16)Bimekizumab 160 mg Q4W (up to Week 16)
Change From Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Total Score at Week 16-1.70 ± 0.21-2.74 ± 0.17
Statistical analysis
  • Placebo (up to Week 16) vs Bimekizumab 160 mg Q4W (up to Week 16) · Regression, Logistic · p = <0.001 · Ls mean difference: -1.04 · 95% CI -1.48 to -0.59
SecondaryPercentage of Participants With Assessment of SpondyloArthritis International Society (ASAS) Partial Remission (PR) at Week 16

The Assessment of SpondyloArthritis International Society partial remission was defined as a score of less than or equal to (\<=) 2 units (on a scale of 0-10, where 0=no disease activity and 10=high disease activity) in each of the 4 domains. These 4 domains included: PGADA assessed disease activity on a scale of 0 \[not active\] to 10 \[very active\], higher score=more disease activity, Pain assessment on a scale of 0 \[no pain\] to 10 \[most severe pain\], higher score=more severity, Function (BASFI) assessed participant's level of ability on a scale of 0 \[easy\] to 10 \[impossible\], Inflammation (morning stiffness intensity and duration, mean of Q5 and Q6 of BASDAI defined as 6 item questionnaire: measured disease activity on a scale of 0 \[none\] to 10 \[severe\], higher score=more disease activity).

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants With Assessment of SpondyloArthritis International Society (ASAS) Partial Remission (PR) at Week 16
percentage of participantsPlacebo (up to Week 16)Bimekizumab 160 mg Q4W (up to Week 16)
Percentage of Participants With Assessment of SpondyloArthritis International Society (ASAS) Partial Remission (PR) at Week 167.224.0
Statistical analysis
  • Placebo (up to Week 16) vs Bimekizumab 160 mg Q4W (up to Week 16) · Regression, Logistic · p = <0.001 · Odds ratio (or): 4.26 · 95% CI 1.93 to 9.39
SecondaryPercentage of Participants With Ankylosing Spondylitis Disease Activity Score Major Improvement (ASDAS-MI) at Week 16

ASDAS-MI is achieved when there is a reduction (improvement) of greater than or equal to (\>=) 2.0 in the Ankylosing Spondylitis Disease Activity Score (ASDAS) relative to Baseline. ASDAS is calculated as the sum of the following components: 1) 0.121 × Total back pain (Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Q2 result), 2) 0.058 × Duration of morning stiffness (BASDAI Q6 result), 3) 0.110 × Patient's Global Assessment of Disease Activity (PGADA), 4) 0.073 × Peripheral pain/swelling (BASDAI Q3 result), 5) 0.579 × (natural logarithm of the C-reactive protein (CRP) \[mg/L\] + 1). Total back pain, PGADA, duration of morning stiffness, peripheral pain/swelling and fatigue are all assessed on a numerical scale (0 \[no disease activity\] to 10 \[high disease activity\] units). High ASDAS scores mean worse disease. If a participant achieves the ASDAS-MI it indicates a major improvement of their disease.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants With Ankylosing Spondylitis Disease Activity Score Major Improvement (ASDAS-MI) at Week 16
percentage of participantsPlacebo (up to Week 16)Bimekizumab 160 mg Q4W (up to Week 16)
Percentage of Participants With Ankylosing Spondylitis Disease Activity Score Major Improvement (ASDAS-MI) at Week 165.425.8
Statistical analysis
  • Placebo (up to Week 16) vs Bimekizumab 160 mg Q4W (up to Week 16) · Regression, Logistic · p = <0.001 · Odds ratio (or): 6.47 · 95% CI 2.67 to 15.65
SecondaryPercentage of Participants With Assessment of SpondyloArthritis International Society (ASAS) 5/6 Response at Week 16

The Assessment of SpondyloArthritis International Society (ASAS) 5/6 response is defined as achieving at least 20% improvement in 5 of 6 domains: PGADA assessed disease activity on a scale of 0 \[not active\] to 10 \[very active\], higher score=more disease activity, Pain assessment on a scale of 0 \[no pain\] to 10 \[most severe pain\], higher score=more severity), Function (BASFI) assessed participant's level of ability on a scale of 0 \[easy\] to 10 \[impossible\], Inflammation (morning stiffness intensity and duration, mean of Q5 and Q6 of BASDAI defined as 6 item questionnaire: measured disease activity on a scale of 0 \[none\] to 10 \[severe\], higher score=more disease activity), spinal mobility (lateral spinal flexion) and high sensitivity C-reactive protein (hs-CRP)\].

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants With Assessment of SpondyloArthritis International Society (ASAS) 5/6 Response at Week 16
percentage of participantsPlacebo (up to Week 16)Bimekizumab 160 mg Q4W (up to Week 16)
Percentage of Participants With Assessment of SpondyloArthritis International Society (ASAS) 5/6 Response at Week 1618.949.3
Statistical analysis
  • Placebo (up to Week 16) vs Bimekizumab 160 mg Q4W (up to Week 16) · Regression, Logistic · p = <0.001 · Odds ratio (or): 4.65 · 4.65% CI 2.51 to 7.57
SecondaryChange From Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI) at Week 16

The Bath Ankylosing Spondylitis Functional Index (BASFI) assesses physical function in comprising 10 items relating to activities during the past week. Each item ranged from 0 ('Easy') to 10 ('Impossible'). The BASFI is the mean of the 10 scores such that the total score ranges from 0 to 10, with lower scores indicating better physical function. A negative value in BASFI change from Baseline indicates an improvement from Baseline. The higher the negative value the better the improvement.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · scores on a scale
Change From Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI) at Week 16
scores on a scalePlacebo (up to Week 16)Bimekizumab 160 mg Q4W (up to Week 16)
Change From Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI) at Week 16-0.95 ± 0.20-2.00 ± 0.16
Statistical analysis
  • Placebo (up to Week 16) vs Bimekizumab 160 mg Q4W (up to Week 16) · Regression, Logistic · p = <0.001 · Ls mean difference: -1.05 · 95% CI -1.48 to -0.63
SecondaryChange From Baseline in Nocturnal Spinal Pain Score Numeric Rating Scale (NRS) at Week 16

Nocturnal spinal pain experienced by ankylosing spondylitis (AS) participants is measured by one question: pain in the spine at night due to AS?. When responding, the participant is to consider the average amount of pain in the preceding week. It is assessed on a numerical scale of 0 (no pain) to 10 (most severe pain) units. A lower score indicates less pain and a negative change represents an improvement.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · scores on a scale
Change From Baseline in Nocturnal Spinal Pain Score Numeric Rating Scale (NRS) at Week 16
scores on a scalePlacebo (up to Week 16)Bimekizumab 160 mg Q4W (up to Week 16)
Change From Baseline in Nocturnal Spinal Pain Score Numeric Rating Scale (NRS) at Week 16-1.68 ± 0.25-3.16 ± 0.20
Statistical analysis
  • Placebo (up to Week 16) vs Bimekizumab 160 mg Q4W (up to Week 16) · Regression, Logistic · p = <0.001 · Ls mean difference: -1.48 · 95% CI -2.00 to -0.96
SecondaryChange From Baseline in Ankylosing Spondylitis Quality of Life (ASQoL) Total Score at Week 16

The Ankylosing Spondylitis Quality of Life (ASQoL), a validated disease-specific 18-item questionnaire, has been developed specifically for measuring health-related quality of life (HRQoL) in participants with ankylosing spondylitis and has shown to be responsive in axial spondyloarthritis (axSpA). Each statement on the ASQoL is given a score of 1=Yes or 0=No. A score of "1" was given where the item was affirmed, indicating adverse quality of life. All item scores were summed to generate the total score ranging from 0 to 18 with a higher score indicating worse health-related quality of life. A negative change from baseline represents an improvement.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · scores on a scale
Change From Baseline in Ankylosing Spondylitis Quality of Life (ASQoL) Total Score at Week 16
scores on a scalePlacebo (up to Week 16)Bimekizumab 160 mg Q4W (up to Week 16)
Change From Baseline in Ankylosing Spondylitis Quality of Life (ASQoL) Total Score at Week 16-3.07 ± 0.41-4.59 ± 0.32
Statistical analysis
  • Placebo (up to Week 16) vs Bimekizumab 160 mg Q4W (up to Week 16) · Regression, Logistic · p = <0.001 · Ls mean difference: -1.52 · 95% CI -2.36 to -0.68
SecondaryChange From Baseline in the Short Form 36-Item Health Survey (SF-36) Physical Component Summary (PCS) Score at Week 16

SF-36 is a 36-item HRQoL instrument with recall period of 4 weeks. Items are grouped into 8 domains: Physical Functioning (10 items), Role Physical (4 items), Bodily Pain (2 items), General Health (5 items), Vitality (4 items), Social Functioning (2 items), Role Emotional (3 items), Mental Health (5 items) and 1 item for Health Transition during last year. PCS and Mental Component Summary (MCS) scores are calculated from 8 domains (excluding Health Transition item). Each of SF-36 derived raw scores range from 0 to 100; higher score = better function. PCS score is calculated from 8 domain scores. It is standardized score ranging from 7.3 to 70.1, with a mean of 50 and SD of 10 in general US population, higher values = better function, and positive change reflects improvement. A PCS score mean below 47 indicates impaired physical functioning. Individual respondent's score that falls outside T-score range of 45 to 55 are outside average general US population range.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · T-score
Change From Baseline in the Short Form 36-Item Health Survey (SF-36) Physical Component Summary (PCS) Score at Week 16
T-scorePlacebo (up to Week 16)Bimekizumab 160 mg Q4W (up to Week 16)
Change From Baseline in the Short Form 36-Item Health Survey (SF-36) Physical Component Summary (PCS) Score at Week 165.17 ± 0.828.54 ± 0.67
Statistical analysis
  • Placebo (up to Week 16) vs Bimekizumab 160 mg Q4W (up to Week 16) · Regression, Logistic · p = <0.001 · Ls mean difference: 3.38 · 95% CI 1.67 to 5.09
SecondaryChange From Baseline in Bath Ankylosing Spondylitis Disease Metrology Index (BASMI) at Week 16

The Bath Ankylosing Spondylitis Disease Metrology Index characterizes the spinal mobility of participants with axial Spondyloarthritis (SpA) and Ankylosing Spondylitis. It is a disease-specific measure consisting of 5 clinical measures to reflect participant axial status: cervical rotation; tragus to wall distance; lateral lumbar flexion; lumbar flexion (modified Schober test); intermalleolar distance. According to the linear definition of the BASMI a score of 0 to 10 was calculated for each item based on the measurement. The mean of the 5 scores provides the total BASMI score (ranging from 0 to 10). The higher the BASMI score, the more severe the participant's limitation of movement due to their axial SpA. A negative value in BASMI change from Baseline indicates an improvement from Baseline. The higher the negative value, the better the improvement.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · scores on a scale
Change From Baseline in Bath Ankylosing Spondylitis Disease Metrology Index (BASMI) at Week 16
scores on a scalePlacebo (up to Week 16)Bimekizumab 160 mg Q4W (up to Week 16)
Change From Baseline in Bath Ankylosing Spondylitis Disease Metrology Index (BASMI) at Week 16-0.17 ± 0.09-0.45 ± 0.07
Statistical analysis
  • Placebo (up to Week 16) vs Bimekizumab 160 mg Q4W (up to Week 16) · Regression, Logistic · p = 0.006 · Ls mean difference: -0.28 · 95% CI -0.47 to -0.08
SecondaryChange From Baseline in the Maastricht Ankylosing Spondylitis Enthesitis (MASES) Index in the Subgroup of Participants With Enthesitis at Baseline at Week 16

The Maastricht Ankylosing Spondylitis Enthesitis is an index that measures the severity (ie, intensity and extent) of enthesitis through the assessment of 13 entheses (bilateral costochondral 1, costochondral 7, anterior superior iliac spine, posterior iliac spine, iliac crest and proximal insertion of the Achilles tendon sites, and the fifth lumbar vertebral body spinous process), each scored as 0 or 1 and then summed for a possible score of 0 to 13. A higher score reflects higher severity and a negative change represents an improvement.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · scores on a scale
Change From Baseline in the Maastricht Ankylosing Spondylitis Enthesitis (MASES) Index in the Subgroup of Participants With Enthesitis at Baseline at Week 16
scores on a scalePlacebo (up to Week 16)Bimekizumab 160 mg Q4W (up to Week 16)
Change From Baseline in the Maastricht Ankylosing Spondylitis Enthesitis (MASES) Index in the Subgroup of Participants With Enthesitis at Baseline at Week 16-1.04 ± 0.33-2.12 ± 0.26
Statistical analysis
  • Placebo (up to Week 16) vs Bimekizumab 160 mg Q4W (up to Week 16) · Regression, Logistic · p = 0.003 · Ls mean difference: -1.08 · 95% CI -1.79 to -0.38
SecondaryPercentage of Participants With Enthesitis-free State at Week 16 Based on the Maastricht Ankylosing Spondylitis Enthesitis Index in the Subgroup of Participants With Enthesitis at Baseline

The Maastricht Ankylosing Spondylitis Enthesitis is an index that measures the severity (ie, intensity and extent) of enthesitis through the assessment of 13 entheses (bilateral costochondral 1, costochondral 7, anterior superior iliac spine, posterior iliac spine, iliac crest and proximal insertion of the Achilles tendon sites, and the fifth lumbar vertebral body spinous process) each scored as 0 or 1 and then summed for a possible score of 0 to 13. Enthesitis free state is defined as having a MASES score of 0. A higher score reflects higher severity and a negative change represents an improvement.

Time frame:
Baseline, Week 16
Reported as:
Number · percentage of participants
Percentage of Participants With Enthesitis-free State at Week 16 Based on the Maastricht Ankylosing Spondylitis Enthesitis Index in the Subgroup of Participants With Enthesitis at Baseline
percentage of participantsPlacebo (up to Week 16)Bimekizumab 160 mg Q4W (up to Week 16)
Percentage of Participants With Enthesitis-free State at Week 16 Based on the Maastricht Ankylosing Spondylitis Enthesitis Index in the Subgroup of Participants With Enthesitis at Baseline32.851.5
Statistical analysis
  • Placebo (up to Week 16) vs Bimekizumab 160 mg Q4W (up to Week 16) · Regression, Logistic · p = 0.006 · Odds ratio (or): 2.47 · 95% CI 1.30 to 4.68
SecondaryPercentage of Participants With Treatment-emergent Adverse Events (TEAEs) During the Study

TEAEs are defined as those AEs that have a start date on or following the first dose of study treatment through the final dose of study treatment + 140 days (covering the 20-week Safety follow up (SFU) period). TEAEs were analyzed and have been reported for Double Blind Treatment Period (Safety set),Maintenance Period (MP) (Maintenance Set) and Overall Period (Safety set) which includes all participants who received BKZ 60 mg Q4W during the study.

Time frame:
From Baseline (Day 1) until Safety-Follow-Up (up to Week 68)
Reported as:
Number · percentage of participants
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) During the Study
percentage of participantsDouble Blind Treatment Period (up to Week 16): PlaceboDouble Blind Treatment Period (up to Week 16): Bimekizumab 160 mg Q4WMaintenance Period (Week 16 up to Week 52): Bimekizumab 160 mg Q4WOverall Period (up to Week 48 + 20 Weeks SFU): Bimekizumab 160 mg Q4W
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) During the Study43.254.368.375.8
SecondaryPercentage of Participants With Treatment-emergent Serious Adverse Events (SAEs) During the Study

A serious adverse event (SAE) is any untoward medical occurrence that at any dose resulted in 1) Death, 2) Life-threatening (Life-threatening does not include a reaction that might have caused death had it occurred in a more severe form.), 3) Significant or persistent disability/incapacity, 4) Congenital anomaly/birth defect (including that occurring in a fetus), 5) Important medical event that, based upon appropriate medical judgment, may jeopardize the participant or participant may require medical or surgical intervention to prevent 1 of the other outcomes listed in the definition of serious (Important medical events may include, but are not limited to, potential Hy's Law \[see allergic bronchospasm requiring intensive treatment in an emergency room or at home, blood dyscrasias that do not result in inpatient hospitalization, or the development of drug dependency or drug abuse.)

Time frame:
From Baseline (Day 1) until Safety-Follow-Up (up to Week 68)
Reported as:
Number · percentage of participants
Percentage of Participants With Treatment-emergent Serious Adverse Events (SAEs) During the Study
percentage of participantsDouble Blind Treatment Period (up to Week 16): PlaceboDouble Blind Treatment Period (up to Week 16): Bimekizumab 160 mg Q4WMaintenance Period (Week 16 up to Week 52): Bimekizumab 160 mg Q4WOverall Period (up to Week 48 + 20 Weeks SFU): Bimekizumab 160 mg Q4W
Percentage of Participants With Treatment-emergent Serious Adverse Events (SAEs) During the Study0.92.34.76.1
SecondaryPercentage of Participants With Treatment-emergent Adverse Events (TEAEs) Leading to Withdrawal From Investigational Medicinal Product (IMP) During the Study

TEAEs are defined as those AEs that have a start date on or following the first dose of study treatment through the final dose of study treatment + 140 days (covering the 20-week SFU period).

Time frame:
From Baseline (Day 1) until Safety-Follow-Up (up to Week 68)
Reported as:
Number · percentage of participants
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) Leading to Withdrawal From Investigational Medicinal Product (IMP) During the Study
percentage of participantsDouble Blind Treatment Period (up to Week 16): PlaceboDouble Blind Treatment Period (up to Week 16): Bimekizumab 160 mg Q4WMaintenance Period (Week 16 up to Week 52): Bimekizumab 160 mg Q4WOverall Period (up to Week 48 + 20 Weeks SFU): Bimekizumab 160 mg Q4W
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) Leading to Withdrawal From Investigational Medicinal Product (IMP) During the Study03.22.84.8

Adverse events

Collected over From Baseline (Day 1) until Safety-Follow-Up (up to Week 68). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Double Blind Treatment Period (up to Week 16): Placebo0/111 (0%)1/111 (0.9%)16/111 (14.4%)
Double Blind Treatment Period (up to Week 16): Bimekizumab 160 mg Q4W0/221 (0%)5/221 (2.3%)43/221 (19.5%)
Maintenance Period (Week 16 up to Week 52): Bimekizumab 160 mg Q4W0/319 (0%)15/319 (4.7%)64/319 (20.1%)
Overall Period (up to Week 48 + 20 Weeks SFU): Bimekizumab 160 mg Q4W0/330 (0%)20/330 (6.1%)95/330 (28.8%)
Most frequent serious events
Showing 10 of 21
Most frequent serious events
EventDouble Blind Treatment Period (up to Week 16): PlaceboDouble Blind Treatment Period (up to Week 16): Bimekizumab 160 mg Q4WMaintenance Period (Week 16 up to Week 52): Bimekizumab 160 mg Q4WOverall Period (up to Week 48 + 20 Weeks SFU): Bimekizumab 160 mg Q4W
SyncopeNervous system disorders0/1110/2214/3194/330
Viral infectionInfections and infestations1/1110/2210/3190/330
DepressionPsychiatric disorders1/1110/2210/3190/330
GoitreEndocrine disorders0/1111/2210/3191/330
Colitis ulcerativeGastrointestinal disorders0/1111/2210/3191/330
Crohn's diseaseGastrointestinal disorders0/1111/2210/3191/330
CholelithiasisHepatobiliary disorders0/1111/2210/3191/330
Hepatitis AInfections and infestations0/1111/2210/3191/330
Sinus node dysfunctionCardiac disorders0/1110/2211/3191/330
Hiatus herniaGastrointestinal disorders0/1110/2211/3191/330
Most frequent other events
Most frequent other events
EventDouble Blind Treatment Period (up to Week 16): PlaceboDouble Blind Treatment Period (up to Week 16): Bimekizumab 160 mg Q4WMaintenance Period (Week 16 up to Week 52): Bimekizumab 160 mg Q4WOverall Period (up to Week 48 + 20 Weeks SFU): Bimekizumab 160 mg Q4W
NasopharyngitisInfections and infestations4/11117/22117/31930/330
Upper respiratory tract infectionInfections and infestations8/1116/22116/31921/330
Oral CandidiasisInfections and infestations0/11110/22112/31920/330
DiarrhoeaGastrointestinal disorders1/1117/22112/31918/330
HeadacheNervous system disorders5/1119/22111/31918/330

Baseline characteristics

Baseline Characteristics refer to the Safety Set which consisted of all randomized study participants who received at least one dose of the investigational medicinal product (IMP).

Age, Categorical
Age, Categorical(Participants)Placebo (up to Week 16)Bimekizumab 160 mg Q4W (up to Week 16)Total
<=18 years000
Between 18 and 65 years109212321
>=65 years2911
Age, Continuous
Age, Continuous(years)Placebo (up to Week 16)Bimekizumab 160 mg Q4W (up to Week 16)Total
Mean39.2 ± 12.641.0 ± 12.140.4 ± 12.3
Sex: Female, Male
Sex: Female, Male(Participants)Placebo (up to Week 16)Bimekizumab 160 mg Q4W (up to Week 16)Total
Female316192
Male80160240
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Placebo (up to Week 16)Bimekizumab 160 mg Q4W (up to Week 16)Total
Asian203757
Black101
White90177267
Other/Mixed033
Missing044
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Placebo (up to Week 16)Bimekizumab 160 mg Q4W (up to Week 16)Total
Hispanic or Latino123
Not Hispanic or Latino110218328
Missing011
08

Study locations

83 sites
  • As0011 50131
    Mesa, Arizona 85210, United States
  • As0011 50052
    Phoenix, Arizona 85032, United States
  • As0011 50058
    Phoenix, Arizona 85037, United States
  • As0011 50062
    Sun City, Arizona 85351, United States
  • As0011 50060
    Upland, California 91786, United States
  • As0011 50056
    Sarasota, Florida 34239, United States
  • As0011 50015
    Hagerstown, Maryland 21740, United States
  • As0011 50016
    St Louis, Missouri 63141, United States
  • As0011 50054
    Oklahoma City, Oklahoma 73103, United States
  • As0011 50020
    Duncansville, Pennsylvania 16635, United States
  • As0011 50001
    Jackson, Tennessee 38305, United States
  • As0011 50012
    Memphis, Tennessee 38119, United States
  • As0011 50057
    Dallas, Texas 75231, United States
  • As0011 50036
    Mesquite, Texas 75150, United States
  • As0011 40004
    Brussels, Belgium
  • As0011 40003
    Genk, Belgium
  • As0011 40001
    Ghent, Belgium
  • As0011 40006
    Plovdiv, Bulgaria
  • As0011 40007
    Plovdiv, Bulgaria
  • As0011 40005
    Sofia, Bulgaria
  • As0011 40008
    Sofia, Bulgaria
  • As0011 20040
    Beijing, China
  • As0011 20021
    Chengdu, China
  • As0011 20019
    Guangzhou, China
  • As0011 20034
    Hefei, China
  • As0011 20024
    Nanjing, China
  • As0011 20018
    Shanghai, China
  • As0011 20020
    Shanghai, China
  • As0011 20026
    Shanghai, China
  • As0011 20025
    Wenzhou, China
  • As0011 40011
    Brno, Czechia
  • As0011 40009
    Pardubice, Czechia
  • As0011 40013
    Prague, Czechia
  • As0011 40014
    Prague, Czechia
  • As0011 40015
    Prague, Czechia
  • As0011 40016
    Prague, Czechia
  • As0011 40010
    Uherské Hradiště, Czechia
  • As0011 40012
    Zlín, Czechia
  • As0011 40018
    Boulogne-Billancourt, France
  • As0011 40022
    Limoges, France
  • As0011 40025
    Berlin, Germany
  • As0011 40028
    Berlin, Germany
  • As0011 40029
    Hamburg, Germany
  • As0011 40024
    Hanover, Germany
  • As0011 40027
    Herne, Germany
  • As0011 40078
    Leipzig, Germany
  • As0011 40026
    Ratingen, Germany
  • As0011 40032
    Debrecen, Hungary
  • As0011 40031
    Szeged, Hungary
  • As0011 40033
    Székesfehérvár, Hungary
  • As0011 40080
    Szombathely, Hungary
  • As0011 20030
    Chūōku, Japan
  • As0011 20047
    Himeji-shi, Japan
  • As0011 20045
    Kita-gun, Japan
  • As0011 20065
    Kitakyushu, Japan
  • As0011 20037
    Osaka, Japan
  • As0011 20084
    Saga, Japan
  • As0011 20048
    Saitama, Japan
  • As0011 20031
    Sapporo, Japan
  • As0011 20042
    Sasebo, Japan
  • As0011 20032
    Suita, Japan
  • As0011 20035
    Tokyo, Japan
  • As0011 40034
    Amsterdam, Netherlands
  • As0011 40038
    Elblag, Poland
  • As0011 40042
    Krakow, Poland
  • As0011 40037
    Lublin, Poland
  • As0011 40044
    Poznan, Poland
  • As0011 40040
    Torun, Poland
  • As0011 40041
    Warsaw, Poland
  • As0011 40039
    Wroclaw, Poland
  • As0011 40043
    Wroclaw, Poland
  • As0011 40045
    A Coruña, Spain
  • As0011 40046
    Córdoba, Spain
  • As0011 40047
    Madrid, Spain
  • As0011 40048
    Santiago de Compostela, Spain
  • As0011 40049
    Seville, Spain
  • As0011 40052
    Ankara, Turkey (Türkiye)
  • As0011 40053
    Ankara, Turkey (Türkiye)
  • As0011 40050
    Istanbul, Turkey (Türkiye)
  • As0011 40057
    Edinburgh, United Kingdom
  • As0011 40056
    Leeds, United Kingdom
  • As0011 40054
    London, United Kingdom
  • As0011 40055
    Norwich, United Kingdom
09

References and documents

Publications

  • van der Heijde D, Deodhar A, Baraliakos X, Brown MA, Dobashi H, Dougados M, Elewaut D, Ellis AM, Fleurinck C, Gaffney K, Gensler LS, Haroon N, Magrey M, Maksymowych WP, Marten A, Massow U, Oortgiesen M, Poddubnyy D, Rudwaleit M, Shepherd-Smith J, Tomita T, Van den Bosch F, Vaux T, Xu H. Efficacy and safety of bimekizumab in axial spondyloarthritis: results of two parallel phase 3 randomised controlled trials. Ann Rheum Dis. 2023 Apr;82(4):515-526. doi: 10.1136/ard-2022-223595. Epub 2023 Jan 17. PubMed 36649967 ↗
  • Navarro-Compan V, Ramiro S, Deodhar A, Mease PJ, Rudwaleit M, de la Loge C, Fleurinck C, Taieb V, Morup MF, Massow U, Kay J, Magrey M. Association of clinical response criteria and disease activity levels with axial spondyloarthritis core domains: results from two phase 3 randomised studies, BE MOBILE 1 and 2. RMD Open. 2024 Apr 10;10(2):e004040. doi: 10.1136/rmdopen-2023-004040. PubMed 38599650 ↗
  • Dubreuil M, Navarro-Compan V, Boonen A, Gaffney K, Gensler LS, de la Loge C, Vaux T, Fleurinck C, Massow U, Taieb V, Morup MF, Deodhar A, Rudwaleit M. Improved physical functioning, sleep, work productivity and overall health-related quality of life with bimekizumab in patients with axial spondyloarthritis: results from two phase 3 studies. RMD Open. 2024 Jun 4;10(2):e004202. doi: 10.1136/rmdopen-2024-004202. PubMed 38834351 ↗
  • Ramiro S, Poddubnyy D, Mease PJ, Lopez-Medina C, Kim M, Massow U, Taieb V, Kragstrup TW, McGonagle D. Sustained resolution of enthesitis and peripheral arthritis over 104 weeks with bimekizumab in axial spondyloarthritis. RMD Open. 2025 Oct 22;11(4):e005969. doi: 10.1136/rmdopen-2025-005969. PubMed 41125403 ↗
  • Nikiphorou E, Tillett W, Deodhar A, Dubreuil M, Gossec L, Hwang M, Lubrano E, Machado PM, Rudwaleit M, de Wit M, Kavanagh S, de la Loge C, Ink B, Lambert J, Morup M, Boonen A, Walsh J. Effect of Bimekizumab Treatment on Health Status, Work Productivity, and Productivity Costs Through 3 Years in Axial Spondyloarthritis and Psoriatic Arthritis. J Rheumatol. 2026 Aug 1:jrheum.2026-0104. doi: 10.3899/jrheum.2026-0104. Online ahead of print. PubMed 42386286 ↗
  • Rudwaleit M, Ramiro S, Poddubnyy D, Magrey M, van der Horst-Bruinsma IE, Deodhar A, Taieb V, Kavanagh S, de Peyrecave N, Gensler LS. Bimekizumab efficacy in male and female patients with axial spondyloarthritis: 52-week results from the Phase 3 BE MOBILE rials. Rheumatology (Oxford). 2026 Aug 14:keag425. doi: 10.1093/rheumatology/keag425. Online ahead of print. PubMed 42605056 ↗
  • Baraliakos X, Deodhar A, van der Heijde D, Van den Bosch F, Magrey M, Maksymowych WP, Tomita T, Xu H, Coarse J, Prajapati C, Manente M, Marten A, Gensler LS. Bimekizumab Long-Term Safety and Efficacy Across the Spectrum of Axial Spondyloarthritis Over 3 Years: Results From 2 Phase III Studies. J Rheumatol. 2026 Aug 1:jrheum.2026-0113. doi: 10.3899/jrheum.2026-0113. Online ahead of print. PubMed 42297437 ↗
  • Navarro-Compan V, Kiltz U, Mease PJ, Dubreuil M, Gaffney K, Deodhar A, de la Loge C, Prajapati C, Kavanagh S, Marzo-Ortega H. Bimekizumab treatment for sustained improvements in patient symptoms and health-related quality of life to 3 years in axial spondyloarthritis: results from the BE MOBILE studies and their open-label extension. RMD Open. 2026 May 13;12(2):e006670. doi: 10.1136/rmdopen-2025-006670. PubMed 42128532 ↗
  • Mease PJ, Merola JF, Magrey M, Nash P, Poddubnyy D, Lebwohl M, Bajracharya R, Ink B, Marten A, Manente M, Peterson L, White K, Gensler LS. Bimekizumab longer-term safety profile in adult patients with axial spondyloarthritis or psoriatic arthritis: an updated analysis of six phase IIb/III clinical studies. RMD Open. 2026 Mar 10;12(1):e006174. doi: 10.1136/rmdopen-2025-006174. PubMed 41807031 ↗
  • Marzo-Ortega H, Navarro-Compan V, Dubreuil M, Mease PJ, Magrey M, Rudwaleit M, D'Agostino MA, Gaffney K, Kay J, de la Loge C, Massow U, Taieb V, Vaux T, Deodhar A. Sustained improvements in spinal pain, morning stiffness, fatigue, sleep, physical function and overall health-related quality of life with bimekizumab in patients with axial spondyloarthritis: 2-year results from two phase 3 studies. RMD Open. 2025 Nov 28;11(4):e006013. doi: 10.1136/rmdopen-2025-006013. PubMed 41314667 ↗
  • Mease PJ, Gensler LS, Orbai AM, Warren RB, Bajracharya R, Ink B, Marten A, Massow U, Shende V, Manente M, Peterson L, White K, Landewe R, Poddubnyy D. Long-term safety of bimekizumab in adult patients with axial spondyloarthritis or psoriatic arthritis: pooled results from integrated phase IIb/III clinical studies. RMD Open. 2025 Apr 6;11(2):e005026. doi: 10.1136/rmdopen-2024-005026. PubMed 40194794 ↗
  • Navarro-Compan V, Rudwaleit M, Dubreuil M, Magrey M, Marzo-Ortega H, Mease PJ, Walsh JA, Dougados M, de la Loge C, Fleurinck C, Massow U, Vaux T, Taieb V, Deodhar A. Improved Pain, Morning Stiffness, and Fatigue With Bimekizumab in Axial Spondyloarthritis: Results From the Phase III BE MOBILE Studies. J Rheumatol. 2025 Jan 1;52(1):23-32. doi: 10.3899/jrheum.2024-0223. PubMed 39406403 ↗
  • Cella D, de la Loge C, Fofana F, Guo S, Ellis A, Fleurinck C, Massow U, Dougados M, Navarro-Compan V, Walsh JA. The Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) scale in patients with axial spondyloarthritis: psychometric properties and clinically meaningful thresholds for interpretation. J Patient Rep Outcomes. 2024 Aug 12;8(1):92. doi: 10.1186/s41687-024-00769-x. PubMed 39133438 ↗
  • Baraliakos X, Deodhar A, van der Heijde D, Magrey M, Maksymowych WP, Tomita T, Xu H, Massow U, Fleurinck C, Ellis AM, Vaux T, Shepherd-Smith J, Marten A, Gensler LS. Bimekizumab treatment in patients with active axial spondyloarthritis: 52-week efficacy and safety from the randomised parallel phase 3 BE MOBILE 1 and BE MOBILE 2 studies. Ann Rheum Dis. 2024 Jan 11;83(2):199-213. doi: 10.1136/ard-2023-224803. PubMed 37793792 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe, or global development is discontinued, and 18 months after trial completion. Investigators may request access to anonymized individual patient-level data and redacted trial documents which may include: analysis-ready datasets, study protocol, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a prespecified time, typically 12 months, on a password protected portal. This plan may change if the risk of re-identifying trial participants is determined to be too high after the trial is completed; in this case and to protect participants, individual patient-level data would not be made available.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe or global development is discontinued, and 18 months after trial completion.

Access criteria: Qualified researchers may request access to anonymized IPD and redacted study documents which may include: raw datasets, analysis-ready datasets, study protocol, blank case report form, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal.

Data sharing details ↗ · www.vivli.org

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2019 to primary completion in Sep 2021, 28 months.

Results were first posted in Oct 2024, 3 years 1 month after primary completion. A results delay was requested in Sep 2022.

Of 38 industry-sponsored phase 3 interventional studies under Spondylitis, Ankylosing, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 28. This study's 28 months is above that.

Counting every sponsor, half of 40 studies reached it within 21 months; a quarter within 15 and three quarters within 32.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 23, 2019
First posted
Apr 26, 2019
StartActual
Apr 25, 2019
Primary completionActual
Sep 3, 2021
CompletionActual
Aug 8, 2022
Results delay requested
Sep 1, 2022
Results first posted
Oct 10, 2024
Last update
Sep 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 42605056 ↗
Sep 25, 2026
Show all 1 update
  1. Sep 25, 2026
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 42605056 ↗
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT03928743
Lead sponsor
UCB Biopharma SRL
Responsible party
Sponsor
First posted
Apr 26, 2019
Start date
Apr 25, 2019
Primary completion
Sep 3, 2021
Completion
Aug 8, 2022
Results posted
Oct 10, 2024
Last update
Sep 25, 2026

Study contacts

UCB Cares
study director · 001 844 599 2273 (UCB)

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bimekizumab

Start the discussion